ASCO 2022 | MRD monitoring in patients with R/R B-cell NHL receiving anti-CD19 CAR T-cell therapy.
Meryl D. Colton
• 4 Jun 2022
The advent of CAR-T cell therapy has improved the historically poor outcomes for patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL), however, relapse is still frequent. In this interview, Meryl D. Colton, MD, University of Colorado, Denver, CO, discusses the use of molecular disease monitoring in patients with R/R B-cell NHL receiving anti-CD19 CAR-T cell therapy. The study demonstrated that monitoring cell-free DNA is a sensitive and specific method to detect disease response and relapse. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
